Background: Prostate cancer that recurs after initial treatment inevitably progresses to
| INTRODUCTION
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in American men. Despite high response rates to initial androgen deprivation therapy, most patients with advanced disease will progress to metastatic castrationresistant prostate cancer (mCRPC). First-line treatments for mCRPC include targeting the androgen receptor (AR) axis with nextgeneration AR signaling inhibitors such as abiraterone acetate and enzalutamide (ENZ). While these therapies provide clinically meaningful benefits, responses are not durable and patients eventually progress on treatment.
1,2 Many patients exhibit primary (de novo) drug resistance, and patients that do respond will inevitably develop resistance, leading to disease progression and limited survival.
Therefore, it is critical to identify improved therapeutic strategies for this lethal form of prostate cancer.
Activation of apoptosis in response to anticancer therapies is known to be a critical mechanism to reduce tumor burden and achieve favorable therapeutic response rates. For the treatment of prostate cancer, several early studies demonstrated that the initial rapid responses and tumor involution observed in response to androgen withdrawal is mediated by apoptotic cell death. 3 Moreover, it was shown that AR inhibition with ENZ induces tumor regression through apoptosis in CRPC xenograft studies. 4 Our group recently demonstrated that targeting inhibitor of apoptosis proteins (cIAP1/ 2), which block death receptor (or extrinsic) pathway signaling, increases response and sensitivity to ENZ in CRPC cell line models, providing further evidence that engaging apoptosis is likely critical to increasing activity of AR antagonists. 5 The intrinsic (or mitochondrial) pathway of apoptosis is a major apoptotic mechanism regulated by the BCL2 family proteins through a complex network of protein-protein interactions. The BCL-2 family consists of antiapoptotic BCL-2, BCL-xL, MCL-1, BCL-w, proapoptotic effectors BAX and BAK, and the proapoptotic BH3-only proteins BIM, BID, BAD, PUMA, and NOXA. The balance of the proapoptotic and antiapoptotic family members determines whether BAX and BAK are activated leading to mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome c and second mitochondria-derived activator of apoptosis, followed by caspase-9 activation, culminating in cell-wide proteolysis and death. 6 Antiapoptotic BCL-2 proteins are frequently overexpressed in cancer and are associated with an aggressive, treatment-refractory disease. In prostate cancer, several studies demonstrate that overexpression of antiapoptotic BCL2 proteins are adverse prognostic factors associated with disease progression and therapy resistance. [7] [8] [9] Increased expression of these antiapoptotic proteins can suppress apoptosis by sequestering the proapoptosis players and preventing activation BAX and BAK. Therefore, targeting the antiapoptotic BCL-2 proteins is an attractive strategy to lower the apoptotic threshold and increase therapeutic response in prostate tumors. In this study, we identify the BCL2 family proteins that block apoptosis in response to ENZ and identify multiple strategies to target these proteins and enhance the action of ENZ in CRPC cell line models. 
| MATERIALS AND METHODS

| Cell lines and reagents
| Viability assays
Viability was measured using the CellTiter-GLO luminescent assay according to the manufacturer's instructions (Promega). Briefly, cells
were seeded into 96-well plates at a density to permit exponential growth throughout the length of the assay 24 hours before drug treatment. Viability was detected by luminescent signal 72 hours after drug treatment using a Victor X1 Luminescence Plate Reader (Perkin Elmer). Viability is displayed as percent of the untreated control. IC 50 values were calculated using Prism v5.02 (GraphPad, San Diego, CA).
| Clonogenic survival
Cells were seeded into six-well plates at a density to permit exponential growth throughout the length of the assay 24 hours before drug treatment. Cells were treated every 72 hours over the course of 14 days after which surviving colonies were stained with 0.1% crystal violet and quantified using ImageJ software.
| Western blot analysis
Immunoblotting was conducted as previously described with minor modifications. 10 Briefly, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer supplemented with Halt Protease and Phosphatase Inhibitor Cocktail. Total protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and stained with the indicated primary antibodies followed by horseradish peroxidase-linked secondary antibodies.
Protein visualization was achieved by enhanced chemiluminescence detection. The quantitative polymerase chain reaction reactions were run using ABI-7500 FAST real-time PCR system (Applied Biosystems).
| Protein complex immunoprecipitation
Samples were run in triplicate for a total of three separate experiments.
| Statistical analysis
Statistical significance was assessed by the Student t test (two-tailed distribution, two-sample, and unequal variance) and considered statistically significant with P < .05. We recently demonstrated that extrinsic pathway signaling is required for enzalutamide-induced apoptosis. We showed that death receptor engagement with TNF-α mediates activation of caspase 8 in response to combination treatment with IAP inhibitor and ENZ, and this signaling is required for apoptotic response. 5 The mitochondrial apoptosis pathway can be initiated in response to various cellular stressors such as DNA damage and hormone withdrawal. 11 Importantly, engagement of the extrinsic apoptosis pathway can also activate mitochondrial apoptosis, providing a mechanism to amplify the apoptotic signal through activation of both pathways. 12 This mechanism is initiated via death receptor binding and activation of We, therefore, hypothesized that sensitivity to ENZ reflects proximity to an apoptotic threshold that is determined by BCL2 protein signaling. To identify the BCL2 proteins that promote survival in response to ENZ, we systematically treated cells with the BH3-mimetics tested above (designed to target BCL-2, BCL-xL, or MCL-1) in combination with ENZ and measured viability and apoptosis. Analysis of LNCaP cells in Figure 3E 
| BH3 mimetics disrupt BCL2 protein interactions to activate proapoptosis signaling in CRPC cells treated with AR antagonist
Protein complexes between the BCL2 family proteins are critical in regulating MOMP and activation of apoptosis. 17 To determine the BCL2 signaling mechanisms blocking apoptosis in the CRPC cell lines, we used immunoprecipitation to identify the BCL2 protein interactions in response to ENZ and BH3 mimetic treatment. We focused on the BH3-only protein BIM since it is a direct activator of BAX/BAK and a sensitizer (antagonist) to all the antiapoptotic BCL2 protein members. 18 As shown in untreated C4-2 cells, both BIM and BAX are mimetics disrupts these interactions and permits apoptosis activation.
| PI3K/Akt blockade indirectly activates proapoptosis signaling and sensitizes CRPC cells to AR antagonist
Our results demonstrate that BCL-xL and MCL-1 are critical for antiapoptotic signaling in response to ENZ. Furthermore, we show that BCL-xL and MCL-1 can function cooperatively to sequester proapoptotic proteins and prevent apoptosis, demonstrating that dual inhibition of both proteins is required for maximum apoptotic response and increased ENZ sensitivity. Since the translational feasibility of using a triplet treatment approach is currently unlikely, we tested obatoclax, a pan-BCL2 inhibitor with activity against BCL-2, BCL-xL, and MCL-1 in combination with ENZ ( Figure 5A ). As shown, combined treatment with obatoclax potently induces apoptosis in 22Rv1 cells. However, due to severe toxicity obatoclax has been eliminated from further clinical development. 19, 20 To identify a potential strategy for inhibition of BCL-xL, we considered its biological antagonist, BAD. The proapoptotic function of BAD is negatively regulated through phosphorylation by Akt, where upstream activation of Akt leads to inhibitory BAD phosphorylation at Ser136 and subsequent 14-3-3 sequestration. 21 Since PTEN is frequently deleted in advanced prostate cancer, and results in constitutive activation of the PI3K/Akt pathway, we hypothesized Indeed, intratumoral androgens and AR transcriptional activity were nearly undetectable with treatment, however complete responses were limited, with some patients demonstrating disease progression.
These studies indicate that even with a near total reduction of AR activity, the tumor cell population is not eliminated. Consistent with previous studies, we did not observe BCL-2, BCLxL, or MCL-1 expression levels to be predictive of response to the BH3 mimetics tested. As shown here, the interactions between 
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